中华航海医学与高气压医学杂志
中華航海醫學與高氣壓醫學雜誌
중화항해의학여고기압의학잡지
CHINESE JOURNAL OF NAUTICAL MEDICINE AND HYPERBARIC MEDICINE
2010年
4期
210-212
,共3页
热衣汗·阿布力米提%米尔妮萨·如则麦麦提%热孜完古丽·艾热提
熱衣汗·阿佈力米提%米爾妮薩·如則麥麥提%熱孜完古麗·艾熱提
열의한·아포력미제%미이니살·여칙맥맥제%열자완고려·애열제
高压氧%脑梗死%依达拉奉%凝血酶原时间%纤维蛋白原
高壓氧%腦梗死%依達拉奉%凝血酶原時間%纖維蛋白原
고압양%뇌경사%의체랍봉%응혈매원시간%섬유단백원
Hyperbaric oxygen%Acute cerebral infarction%Edaravone%Prothrombin time%Fibrinogen
目的 观察依达拉奉联合高压氧(HBO)治疗83例急性脑梗死患者的效果.方法 166例急性脑梗死患者分为依达拉奉治疗组(药物组)和依达拉奉联合HBO治疗组(HBO综合组),每组83例.药物组每天2次静脉滴注依达拉奉30 mg,HBO综合组除用依达拉奉治疗外,每天行HBO治疗1次,压力0.22 MPa,时间80 min,共治疗21 d,对2组患者住院3周后进行神经功能评分,以观察疗效,检测凝血酶原时间(PT)和纤维蛋白原(FIB)水平.结果 治疗第2周、第3周HBO综合组神经功能评分和疗效显著高于治疗前和药物组(P<0.05或0.01);HBO综合组PT的增高幅度大于药物组(P<0.05),血浆FIB水平则显著低于药物组(P<0.05或0.01).结论 依达拉奉联合HBO治疗的效果优于单纯用药,且HBO综合治疗可使PT增高和FIB水平显著降低.
目的 觀察依達拉奉聯閤高壓氧(HBO)治療83例急性腦梗死患者的效果.方法 166例急性腦梗死患者分為依達拉奉治療組(藥物組)和依達拉奉聯閤HBO治療組(HBO綜閤組),每組83例.藥物組每天2次靜脈滴註依達拉奉30 mg,HBO綜閤組除用依達拉奉治療外,每天行HBO治療1次,壓力0.22 MPa,時間80 min,共治療21 d,對2組患者住院3週後進行神經功能評分,以觀察療效,檢測凝血酶原時間(PT)和纖維蛋白原(FIB)水平.結果 治療第2週、第3週HBO綜閤組神經功能評分和療效顯著高于治療前和藥物組(P<0.05或0.01);HBO綜閤組PT的增高幅度大于藥物組(P<0.05),血漿FIB水平則顯著低于藥物組(P<0.05或0.01).結論 依達拉奉聯閤HBO治療的效果優于單純用藥,且HBO綜閤治療可使PT增高和FIB水平顯著降低.
목적 관찰의체랍봉연합고압양(HBO)치료83례급성뇌경사환자적효과.방법 166례급성뇌경사환자분위의체랍봉치료조(약물조)화의체랍봉연합HBO치료조(HBO종합조),매조83례.약물조매천2차정맥적주의체랍봉30 mg,HBO종합조제용의체랍봉치료외,매천행HBO치료1차,압력0.22 MPa,시간80 min,공치료21 d,대2조환자주원3주후진행신경공능평분,이관찰료효,검측응혈매원시간(PT)화섬유단백원(FIB)수평.결과 치료제2주、제3주HBO종합조신경공능평분화료효현저고우치료전화약물조(P<0.05혹0.01);HBO종합조PT적증고폭도대우약물조(P<0.05),혈장FIB수평칙현저저우약물조(P<0.05혹0.01).결론 의체랍봉연합HBO치료적효과우우단순용약,차HBO종합치료가사PT증고화FIB수평현저강저.
Objective To investigate therapeutic effect of Edaravone combined with HBO on acute cerebral infarction in 83 cases. Methods One hundred and sixty - six cases of acute cerebral infarction were equally divided into two groups, the Edaravone treatment group (the simple medication group) (n = 83) and the Edaravone combined with HBO treatment group (the medication plus HBO group) (n = 83). The simple medication group was administered with an injection of 30 mg Edaravone twice a day, and the medication plus HBO group was treated by Edaravone combined with HBO. Neural function was compared and analyzed between the groups following 3 weeks of treatment to assess therapeutic effects, to monitor prothrombin time (PT), and the level of fibronogen. Results After the second and third week of the treatment, neural functional scores and therapeutic efficacy for the medication plus HBO group were obviously better than those of the simple medication group (P < 0. 05 or 0. 01). The level of PT for the medication plus HBO group was obviously greater (P <0. 05), while the level of serum FIB was significantly lower than that of the simple medication group (P < 0. 05 or 0. 01). Conclusions The therapeutic effect of Edaravone combined with HBO was obviously better than that of the simple medication group. In addition, Edaravone combined with HBO could obviously increase the levels of PT and decrease the levels of FIB.
